MM120 (LSD D-tartrate)

DT120 (formerly MM120, LSD D-tartrate) is a single-dose serotonergic psychedelic in Phase 3 development for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD). The sponsor is Definium Therapeutics (ticker DFTX), the January 2026 rebrand of MindMed [8], running four Phase 3 trials with three topline readouts landing in 2026: Emerge (MDD) in late Q2, Voyage (GAD) in early Q3, and Panorama (GAD) in late Q3 [8]. Phase 2b GAD efficacy data was published in JAMA [1]. The bet is that one supervised dosing session produces months of symptom relief, a commercial model that looks nothing like a daily SSRI. If Phase 3 holds, DT120 would be the first regulated LSD-based therapy in modern psychiatric medicine. The downside scenario is also unusual: functional unblinding (patients can tell whether they got the psychedelic, the same issue the FDA cited in its August 2024 Complete Response Letter to Lykos for MDMA-PTSD [10]), durability uncertainty across the 12-week window, and a regulatory path that requires DEA rescheduling on top of FDA approval. Emerge (MDD) is the first catalyst, not the GAD trials, and arrives effectively at the wire as of this writing. A clean win across one or both indications validates the entire serotonergic psychedelic category, including psilocybin programs at Compass Pathways and others. A miss, particularly a durability shortfall, forces the field to confront whether single-dose psychedelics work commercially or only in tightly supervised research settings.

DT120 is a novel investigational therapeutic. LSD has been Schedule I in the United States since the 1970 Controlled Substances Act, so DT120 has never been FDA-approved in any indication. The compound was branded MM120 under MindMed and renamed DT120 in January 2026 when MindMed rebranded as Definium Therapeutics [8]; all current SEC filings, trial updates, and investor materials use DT120, so investors cross-checking primary sources will encounter only that name. Four active Phase 3 trials run in parallel: Panorama [2] and Voyage [3] in GAD, both active-not-recruiting; Emerge in MDD [4]; and Ascend in MDD [5], whose trial record already uses the DT120 nomenclature. Three of the four trials have topline readouts in 2026: Emerge in late Q2, Voyage in early Q3, and Panorama in late Q3 [8]. The MDD program now leads the readout calendar, not the GAD program. A completed Phase 2 ADHD proof-of-concept (n=53) [6] provides additional low-dose safety read-through. The sponsor holds FDA Breakthrough Therapy Designation for DT120 in GAD, granted on the strength of the Phase 2b results later published in JAMA [1]. Breakthrough designation buys more frequent FDA meetings and the option of rolling review, not a lower efficacy bar. Any approval will require coordinated DEA action, with the most likely path being a Schedule II or III rescheduling for the medical product while the underlying compound stays Schedule I for non-medical use, analogous to how Spravato (esketamine) is handled today.

LSD binds to the 5-HT2A receptor, a serotonin receptor that sits on the surface of cortical neurons, concentrated in layer 5 of the prefrontal cortex. Think of 5-HT2A as a knob that controls how flexibly the brain rewires itself. When activated, it triggers a signaling cascade that opens a window of neuroplasticity, the capacity of neurons to grow new connections and remodel old ones. In healthy brains this happens constantly. In chronic anxiety and depression, the wiring becomes rigid and patients get stuck in repetitive negative thought patterns. The hypothesis is that a single high-dose psychedelic session forces a plasticity window that, combined with the subjective experience itself, lets the patient break the stuck pattern for months at a time. The human genetics are supportive but not loud: Open Targets gives HTR2A an association score of 0.703 for major depressive disorder, meaningful but not Mendelian. The mechanistic case is stronger from precedent. Psilocybin, another 5-HT2A agonist, has shown durable antidepressant effects in Compass Pathways trials. Spravato hits a different receptor (NMDA) but produces a similar acute dissociative experience and is approved and commercially established. The honest read: 5-HT2A agonism is a real biological lever, but whether the durable benefit comes from receptor pharmacology, the subjective psychedelic experience, or the structured therapy wrapped around the dose is still unresolved. That ambiguity matters because it shapes labeling, pricing, and delivery model.

The MDD program leads the readout calendar. Emerge (NCT06941844, n=149) [4] reads out in late Q2 2026, with Ascend (NCT07592689, n=165) [5] further behind. The GAD program follows: Voyage (NCT06741228, n=214) [3] in early Q3 and Panorama (NCT06809595, n=245) [2] in late Q3 2026 [8]. GAD trials use Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12 as the primary endpoint. MDD trials use Montgomery-Asberg Depression Rating Scale (MADRS) at Week 6. A Week 12 primary in GAD is the right call for a single-dose intervention because it actually tests durability, not just acute response. The Week 6 MADRS primary in MDD looks inconsistent with the months-of-benefit marketing pitch but is the conventional MDD primary and was almost certainly the endpoint agreed with FDA at End-of-Phase-2, powered to the Phase 2b effect size; Week 12 durability is a pre-specified secondary endpoint. The commercial implication: if Week 6 hits but the Week 12 secondary shows erosion, the label will reflect that and the months-of-benefit pitch breaks regardless of approval. The sample sizes (149 to 245 per trial) work only if the Phase 2b effect size carries. JAMA Phase 2b GAD data showed a roughly 7-point HAM-A advantage at the 100 mcg dose [1], a large effect by psychiatric trial standards. The comparator in all four Phase 3 trials is placebo, not active control, which is appropriate for a first-in-class compound but invites the functional unblinding criticism head-on. A completed Phase 2 ADHD trial [6] provides low-dose safety bridging data, though the indication itself is unlikely to advance.

The model estimates a 16% chance this drug is eventually approved. That figure starts from the historical approval rate for Phase 3 drugs in this area, which is about 51%, then adjusts based on ten facts about the trial and sponsor. The biggest positive factor is more secondary endpoints than usual; the biggest negatives are the sponsor's thin or weak approval record, weak or limited earlier-phase results, and heavier-than-usual blinding. The remaining factors are close to average for this stage and leave the estimate roughly where the base rate set it.

Five risk buckets, in rough order of importance. Functional unblinding is the single biggest threat, and the FDA has already drawn the line. In August 2024 the FDA issued a Complete Response Letter to Lykos Therapeutics for MDMA-assisted PTSD therapy, citing functional unblinding among its core concerns and requiring an additional Phase 3 trial; the CRL was made public in September 2025 [10]. The FDA stated that participants knowing they received an active psychedelic undermines the trial's ability to measure drug effect separately from expectation. That is the exact regulatory standard Definium will face. Patients who experience a high-dose LSD session know they did not get placebo, which inflates active-arm response and depresses placebo-arm response. FDA reviewers will scrutinize the guess-which-arm-you-were-in analysis closely, and the Lykos precedent means a poorly handled analysis is now a documented path to a CRL, not a hypothetical one. Durability is second. The commercial premise is one dose, months of benefit. If HAM-A scores rebound between Week 8 and Week 12, the differentiation versus daily SSRIs collapses and the pricing model breaks. Safety risk is real but manageable. Acute psychiatric adverse events during the dosing session (severe anxiety, dissociative distress, suicidal ideation) are the predictable on-target signals. 5-HT2B-mediated cardiac valvulopathy, a chronic-dosing concern for older serotonergic drugs, is largely irrelevant under a single-dose paradigm. The rarer tail risk is HPPD, persistent visual disturbances documented at low rates in recreational LSD users. Commercial risk centers on REMS and reimbursement. Any approval will require a Risk Evaluation and Mitigation Strategy modeled on Spravato: certified clinic, monitored administration, no take-home dosing. That bounds the addressable market to patients who can get to a certified clinic and payers who will cover the bundled session. Spravato has had a slow ramp under exactly these constraints. DEA rescheduling adds a regulatory layer no SSRI has to clear. IP risk is the fifth bucket. The active molecule (lysergide) is off-patent; Definium's exclusivity rests on formulation patents around the Catalent Zydis fast-dissolve ODT, method-of-use claims, and the regulatory exclusivity periods that come with NDA approval. A determined competitor could in principle replicate the trial design with a different formulation, though the cost and time to a second Phase 3 would push any fast-follower years behind. Even with a clean efficacy win, the commercial slope will be measured in years, not quarters.

Worth watching, with a specific and imminent catalyst. Emerge (MDD) is the first readout, due in late Q2 2026, which is at or past the wire as of this writing [8]. Voyage (GAD) follows in early Q3 and Panorama (GAD) in late Q3 [8]. The readout windows are already public from the January 2026 rebrand press release and the March 2026 Leerink conference investor update [8], so the watch task is on results, not on guidance. A clean separation on Emerge would validate the MDD program and provide read-through to the much larger Phase 2b-supported GAD trials. The split scenarios matter and the market is likely to price them differently. Emerge miss with Voyage and Panorama hits would still leave a GAD-only commercial path with the stronger Phase 2b precedent, and the stock would be expected to recover most of the loss on the GAD prints. Emerge hit with GAD misses would be the surprise outcome and would force a re-read of why a 5-HT2A agonist works in depression but not in anxiety, despite stronger prior data in anxiety. Financial position is comfortable for the readout cycle: $373.4M in cash and investments at Q1 2026 plus access to a $120M credit facility, stated runway into 2028, Q1 operating expenses of $59.2M [9]. That covers all three readouts and a potential NDA filing without forcing a dilutive raise pre-data, though approval, REMS build-out, and commercial launch would likely require additional capital. The company is small enough that the share price moves binary on each readout, which means the implied probability traded by the market is a useful sanity check on the model's 49.3% score. If the stock trades like a 65% probability and the model says 49%, that gap is the trade or the warning, depending on whether you trust the market or the model on first-in-class psychiatry assets. The MDD second look (Ascend) and any post-Phase 3 NDA review are second-order catalysts behind the three 2026 reads. Not investment advice.